This is a serious public health issue that could potentially affect thousands of women. Our Firm is interested in hearing from anyone who allegedly experienced the spread of undiagnosed cancer following uterine surgery that involved power morcellation.
New York, New York (PRWEB) May 01, 2014
Bernstein Liebhard LLP is investigating potential power morcellator lawsuits (http://www.morcellatorlawsuit2015.com/) in light of the U.S. Food & Drug Administration’s (FDA) recent advisory regarding cancer risks associated with the use of morcellators in hysterectomies and fibroid removal procedures. According to the April 17th FDA advisory, the use of power morcellation during such procedures may promote the spread of undiagnosed uterine cancers. The agency, which is planning to convene an advisory panel meeting to discuss the matter this summer, is now discouraging the use of power morcellation in women undergoing hysterectomies or myomectomies for fibroid removal.
“This is a serious public health issue that could potentially affect thousands of women. Our Firm is interested in hearing from anyone who allegedly experienced the spread of undiagnosed cancer following uterine surgery that involved power morcellation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering hysterectomy cancer lawsuit reviews to women who suffered uterine sarcoma or other cancers allegedly associated with power morcellation.
Power Morcellator Cancer Risks
Power morcellators are used to divide uterine tissue into smaller pieces or fragments so it can be removed through a small incision in the abdomen during laparoscopic uterine surgeries. According to the FDA’s April 17th alert, a review of currently available data indicates that the use of this technology poses a risk of spreading unsuspected cancerous tissue, notably uterine sarcomas, beyond the uterus. The FDA has determined that approximately 1 in 350 women who are undergoing hysterectomy or myomectomy for fibroids suffer from undiagnosed uterine sarcomas. The spread of this cancerous tissue within the abdomen and pelvis significantly worsens a patient’s likelihood of long-term survival, the agency said.
According to a report published by Reuters on April 30th, the advisory has prompted Johnson & Johnson’s Ethicon unit to suspend sales of power morcellators until the FDA can provide further clarification regarding the use of power morcellation in fibroid surgeries.* The Plain Dealer reported on April 28th that the FDA’s statement had also prompted the Cleveland Clinic and some other hospitals to suspend the use of morcellators for uterine surgery pending further guidance from the agency.**
Women who allegedly experienced the spread of undiagnosed uterine cancer due to a power morcellator may be entitled to compensation for medical bills, lost wages, pain and suffering and other damages. For more information on the risks allegedly associated with power morcellation, please visit Bernstein Liebhard LLP's website. To obtain a free, no obligation hysterectomy cancer lawsuit review, please call 800-511-5092.
*reuters.com/article/2014/04/30/us-johnson-johnson-device-idUSKBN0DG06G20140430, Reuters, April 30, 2014
**cleveland.com/healthfit/index.ssf/2014/04/surgical_tool_for_hysterectomy.html, The Plain Dealer, April 28, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP